The Pompe Disease Market was valued at USD 1.70 billion in 2025 and is projected to reach USD 2.51 billion by 2033, growing at a CAGR of 5.00% from 2026 to 2033. The Pompe Disease Market is experiencing consistent growth driven by rising awareness regarding rare genetic disorders, increasing diagnosis rates, advancements in enzyme replacement therapies, and growing investments in rare disease research and treatment development. The expanding availability of newborn screening programs, improved genetic testing capabilities, and increasing focus on early disease identification are encouraging healthcare providers and patients to adopt advanced Pompe disease management solutions.
The growing prevalence of late-onset and infantile Pompe disease cases, combined with advancements in targeted therapies and supportive care approaches, is increasing demand for innovative treatment options globally. Enzyme replacement therapies (ERT), next-generation therapies, and emerging gene therapy approaches are transforming disease management by improving patient outcomes and slowing disease progression. In addition, increasing government initiatives for rare disease treatment, expansion of specialized healthcare centers, and rising collaborations between pharmaceutical companies and research organizations are further supporting the growth of the Pompe Disease Market.